Intraarterial chemotherapy for osteosarcoma: does the result really justify the effort?

[1]  S. Leyvraz,et al.  Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high‐dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS‐86) , 1990, Cancer.

[2]  S. Jacobs,et al.  Intraarterial cisplatin infusion in the management of transitional cell carcinoma of the bladder , 1989, Cancer.

[3]  F. Muggia,et al.  Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-cisplatin in humans. , 1989, Cancer research.

[4]  J. Harrelson,et al.  Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma , 1989, Cancer.

[5]  K. Bland,et al.  A Phase II Study of the Efficacy of Diamminedichloroplatinum (Cisplatin) for the Control of Locally Recurrent and Intransit Malignant Melanoma of the Extremities Using Tourniquet Outflow‐Occlusion Techniques , 1989, Annals of surgery.

[6]  N. Jaffe,et al.  Effect of cumulative courses of intraarterial cis‐diamminedichloroplatin‐ii on the primary tumor in osteosarcoma , 1989, Cancer.

[7]  G. Fiorentini,et al.  Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results. , 1988, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[8]  A. Nanji,et al.  Platinum Concentrations in Human Autopsy Tumor Samples , 1988, American journal of clinical oncology.

[9]  H. Jürgens,et al.  Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Dubousset,et al.  Expérience du protocole T10 dans le service de pédiatrie de l'Institut Gustave-Roussy , 1988 .

[11]  M. Marangolo,et al.  Neoadjuvant Chemotherapy for Osteosarcoma — Results of a Prospective Study , 1988 .

[12]  J. Gentet,et al.  [The reproduction in France of Rosen's protocol for osteosarcomas]. , 1988, Bulletin du cancer.

[13]  J. Ryan,et al.  Recent Concepts in Sarcoma Treatment , 1988, Developments in Oncology.

[14]  C. Fournier,et al.  Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer. , 1987, Cancer research.

[15]  P. Picci,et al.  Neoadjuvant chemotherapy for osteosarcoma of the extremity. , 1987, Clinical orthopaedics and related research.

[16]  M. Tattersall,et al.  Regional chemotherapy with the use of cisplatin and doxorubicin as primary treatment for advanced sarcomas in shoulder, pelvis, and thigh , 1987, Cancer.

[17]  N. Brock,et al.  The Basis of Modern Ifosfamide Therapy1 , 1987 .

[18]  A. Wile,et al.  The Pharmacokinetics of Cisplatin in Experimental Regional Chemotherapy , 1987, Cancer.

[19]  A. Giuliano,et al.  Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Weiner,et al.  Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. , 1986, Cancer treatment reports.

[21]  N. Trapeznikov,et al.  Management of osteogenic sarcoma patients. , 1986, Seminars in surgical oncology.

[22]  W. Ebell,et al.  Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Einhorn Lh,et al.  Complete remission in refractory Burkitt's lymphoma. , 1984 .

[24]  J M Collins,et al.  Pharmacologic rationale for regional drug delivery. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .